This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), safety and tolerability of oral semaglutide in subjects with various degrees of impaired renal function compared to subjects with normal renal function.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
71
Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg
Novo Nordisk Investigational Site
Hradec Králové, Czechia
Novo Nordisk Investigational Site
Prague, Czechia
Novo Nordisk Investigational Site
Budapest, Hungary
Novo Nordisk Investigational Site
Budapest, Hungary
Area under the semaglutide plasma concentration time curve
Time frame: From time 0 to 24 hours after the 10th dosing
Maximum observed semaglutide plasma concentration
Time frame: 0 to 24 hours after the 10th dosing
Area under the SNAC (Sodium N-[8-(2-hydroxybenzoyl) amino] caprylate /salcaprozate sodium) plasma concentration time curve
Time frame: From time 0 to 24 hours after the 10th dosing
Maximum observed SNAC plasma concentration
Time frame: 0 to 24 hours after the 10th dosing
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.